1. Home
  2. TRAK vs KZIA Comparison

TRAK vs KZIA Comparison

Compare TRAK & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TRAK

ReposiTrak Inc.

HOLD

Current Price

$8.25

Market Cap

157.2M

Sector

Technology

ML Signal

HOLD

Logo Kazia Therapeutics Limited

KZIA

Kazia Therapeutics Limited

HOLD

Current Price

$10.65

Market Cap

186.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRAK
KZIA
Founded
1990
1994
Country
United States
Australia
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
157.2M
186.7M
IPO Year
1996
2002

Fundamental Metrics

Financial Performance
Metric
TRAK
KZIA
Price
$8.25
$10.65
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$19.50
AVG Volume (30 Days)
92.6K
329.1K
Earning Date
05-14-2026
06-04-2026
Dividend Yield
0.90%
N/A
EPS Growth
20.69
N/A
EPS
0.28
N/A
Revenue
$21,007,076.00
N/A
Revenue This Year
$6.61
N/A
Revenue Next Year
$10.04
N/A
P/E Ratio
$29.25
N/A
Revenue Growth
4.84
N/A
52 Week Low
$6.94
$4.86
52 Week High
$17.68
$17.40

Technical Indicators

Market Signals
Indicator
TRAK
KZIA
Relative Strength Index (RSI) 53.70 40.08
Support Level $8.11 $10.59
Resistance Level $9.06 $14.85
Average True Range (ATR) 0.28 0.82
MACD 0.07 -0.19
Stochastic Oscillator 74.61 14.69

Price Performance

Historical Comparison
TRAK
KZIA

About TRAK ReposiTrak Inc.

ReposiTrak Inc is a software-as-a-service (SaaS) company based in Murray, Utah, specializing in supply chain management solutions for retailers, suppliers, and wholesalers, prominently in the food industry. The company offers three main product suites: ReposiTrak Compliance Management, ReposiTrak Traceability Network, and ReposiTrak Supply Chain Solutions. These platforms help customers comply with food safety regulations, manage supplier compliance documentation, trace products through the supply chain, and optimize supply chain operations. The company derives revenue from five sources: (i) subscription fees, (ii) transaction-based fees, (iii) professional services fees, (iv) license fees, and (v) hosting and maintenance fees.

About KZIA Kazia Therapeutics Limited

Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.

Share on Social Networks: